Aytu BioScience logo
Aytu BioScience AYTU
$ 2.66 0.0%
report update icon

Quarterly report 2027-Q1
added 11-16-2026

Aytu BioScience Long-Term Debt | AYTU

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt Aytu BioScience

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
9.1 M 10.9 M 10.9 M 14.7 M 15 M 180 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
15 M 180 K 10.1 M

Quarterly Long-Term Debt Aytu BioScience

2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
785 K 853 K 9.55 M 10 M 10.4 M 10 M 10.4 M 1.11 M 9.54 M 9.98 M 10.4 M 15 M - 15 M 1.15 M 1.47 M 1.77 M 2.09 M 2.41 M 15 M 2.76 M 2.62 M 2.87 M 211 K 237 K 725 K 804 K 292 K 314 K 23.4 M 5.13 M 5.04 M 5.13 M 5.04 M - 5.04 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
23.4 M 211 K 5.78 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
13.9 M - - $ 401 M usaUSA
Histogen Histogen
HSTO
5 K - 31.6 % $ 2.12 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
2.47 M - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
437 M - -7.23 % $ 13 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
4.98 M - - $ 1.62 B israelIsrael
Omeros Corporation Omeros Corporation
OMER
87.9 M $ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
977 K $ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
1.36 M - 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
27.6 M - - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
68.8 M - - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
2.55 B - - $ 26.6 B irlandaIrlanda
Provention Bio Provention Bio
PRVB
23.5 M - - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
117 M - - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
30 K $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
3.76 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
15 K $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
41 K - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
21.5 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
1.9 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
188 M $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
8.14 M - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
1.14 M $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
30.8 M - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
136 K - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
9.74 M - -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
20 M - -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
84.7 M $ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
3.74 M - -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
349 K - -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
110 K - -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
216 M - - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
8.3 M - -6.81 % $ 3.04 B usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
388 K - - $ 4.55 M irlandaIrlanda
scPharmaceuticals scPharmaceuticals
SCPH
51.4 M - - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
704 K - - $ 105 M usaUSA
Athersys Athersys
ATHX
7.94 M - 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
246 M - - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
31.5 M - - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
227 M - -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
25 M - -81.12 % $ 4.28 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
19.1 M - -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
24.7 M - - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
485 K - -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
26 K - -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
931 K - -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
5.87 M - - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
1.17 M $ 0.93 -4.11 % $ 10.5 M usaUSA